Continuous Soluble Ferric Pyrophosphate (SFP) Iron Delivery Via Dialysate in Hemodialysis Patients
Status:
Completed
Trial end date:
2013-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare the clinical safety and efficacy of SFP in sparing
the need for erythropoiesis stimulating agents (ESAs) required to maintain hemoglobin (hgb)
levels in chronic hemodialysis subjects who receive SFP via the dialysate versus subjects who
receive conventional dialysate without iron.